Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C6H14O6 |
| Molecular Weight | 182.1718 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
InChI
InChIKey=FBPFZTCFMRRESA-JGWLITMVSA-N
InChI=1S/C6H14O6/c7-1-3(9)5(11)6(12)4(10)2-8/h3-12H,1-2H2/t3-,4+,5-,6-/m1/s1
DescriptionSources: https://www.drugbank.ca/drugs/DB00742 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022368Orig1s000LBL.pdf | https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/013684s091lbl.pdfhttps://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16cc9d47-5382-4237-ab84-f22c5436fe2eCurator's Comment: description was created based on several sources, including:
http://www.sailhome.org/Concerns/Vaccines.html
Sources: https://www.drugbank.ca/drugs/DB00742 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022368Orig1s000LBL.pdf | https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/013684s091lbl.pdfhttps://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16cc9d47-5382-4237-ab84-f22c5436fe2e
Curator's Comment: description was created based on several sources, including:
http://www.sailhome.org/Concerns/Vaccines.html
Sorbitol is a polyhydric alcohol with about half the sweetness of sucrose. Sorbitol occurs naturally and is produced synthetically from glucose. It was formerly used as a diuretic and may still be used as a laxative and in irrigating solutions for some surgical procedures. Used as a non-stimulant laxative via an oral suspension or enema. Sorbitol exerts its laxative effect by drawing water into the large intestine, thereby stimulating bowel movements. Sorbitol plays a vital step in the 'polyol pathway'. The sudden injection of extra sorbitol can ruin the equilibrium of enzymes that regulate the conversion of glucose to fructose in a process associated with the onset of diabetes and its complications. Further, the polyol pathway is involved with a complex network of metabolic activities; disruption leads to a cascade of problems (citations here, here and here) such as mitochondrial failure, cell apoptosis (cell death), and DNA fragmentation. In general, sorbitol induces cell hyperosmotic stress resulting in phosphorylation (uptake of phosphorus into cell) — an important on/off switch regulating enzymes and signaling networks.
CNS Activity
Sources: https://www.anaesthesiamcq.com/FluidBook/fl8_5.phphttps://www.ncbi.nlm.nih.gov/pubmed/?term=26035307
Curator's Comment: Mannitol does not cross the blood-brain barrier so an elevated plasma osmolality due to an infusion of hypertonic mannitol is effective in removing fluid from the brain.
Originator
Sources: https://books.google.ru/books?id=_F1YSezlIzwC&pg=PA268&lpg=PA268&dq=mannitol retrieved from Carbohydrates, p.268Alternative Sweeteners, Third Edition, Revised and Expanded. Ed. Lyn O'Brien-Nabors. CRC Press, 2001 . - pp. 572
Curator's Comment: Manufactured - Atlas Powder Company, Wilmington, Delaware, 1937
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Preventing | Osmitrol Approved UseOsmitrol Injection (Mannitol Injection, USP) is indicated for:
The promotion of diuresis, in the prevention and/or treatment of the oliguric phase of acute renal
failure before irreversible renal failure becomes established;
The reduction of intracranial pressure and treatment of cerebral edema by reducing brain mass;
The reduction of elevated intraocular pressure when the pressure cannot be lowered by other means,
and promoting the urinary excretion of toxic substances. Launch Date1964 |
|||
| Primary | Osmitrol Approved UseOsmitrol Injection (Mannitol Injection, USP) is indicated for:
The promotion of diuresis, in the prevention and/or treatment of the oliguric phase of acute renal
failure before irreversible renal failure becomes established;
The reduction of intracranial pressure and treatment of cerebral edema by reducing brain mass;
The reduction of elevated intraocular pressure when the pressure cannot be lowered by other means,
and promoting the urinary excretion of toxic substances. Launch Date1964 |
|||
| Primary | Osmitrol Approved UseOsmitrol Injection (Mannitol Injection, USP) is indicated for:
The promotion of diuresis, in the prevention and/or treatment of the oliguric phase of acute renal
failure before irreversible renal failure becomes established;
The reduction of intracranial pressure and treatment of cerebral edema by reducing brain mass;
The reduction of elevated intraocular pressure when the pressure cannot be lowered by other means,
and promoting the urinary excretion of toxic substances. Launch Date1964 |
|||
| Diagnostic | ARIDOL Approved UseMannitol, the active ingredient in ARIDOL, is indicated for the assessment of bronchial hyperresponsiveness in patients 6 years of age or older who do not have clinically apparent asthma. Launch Date2010 |
|||
| Palliative | Bronchitol Approved UseBronchitol is indicated for the treatment of cystic fibrosis (CF) in adults aged 18 years and above as
an add-on therapy to best standard of care. Launch Date2012 |
|||
| Primary | SORBITOL 3.3% IN PLASTIC CONTAINER Approved UseRenagel Capsules are indicated for the reduction of serum phosphorus in patients with end-stage renal disease (ESRD). The safety and efficacy of Renagel Capsules in ESRD patients who are not on hemodialysis have not been studied. In hemodialysis patients, Renagel decreases the incidence of
hypercalcemic episodes relative to patients on calcium acetate treatment. Launch Date1978 |
|||
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Stereocontrolled total synthesis of (+)-streptazolin by a palladium-catalyzed reductive diyne cyclization. | 2004-08-20 |
|
| Cytochrome c release occurs via Ca2+-dependent and Ca2+-independent mechanisms that are regulated by Bax. | 2001-06-01 |
|
| Effects of P-glycoprotein on cell volume regulation in mouse proximal tubule. | 2001-05 |
|
| Alveolar epithelial barrier functions in ventilated perfused rabbit lungs. | 2001-05 |
|
| Theoretical description of transdermal transport of hydrophilic permeants: application to low-frequency sonophoresis. | 2001-05 |
|
| Design and validation of an annular shear cell for pharmaceutical powder testing. | 2001-05 |
|
| The production of reactive oxygen species by irradiated camphorquinone-related photosensitizers and their effect on cytotoxicity. | 2001-05 |
|
| Cysteine cross-linking defines part of the dimer and B/C domain interface of the Escherichia coli mannitol permease. | 2001-04-20 |
|
| The effect of Celsior solution on 12-hour cardiac preservation in comparison with University of Wisconsin solution. | 2001-04 |
|
| Effect of high glucose concentration on the synthesis of monocyte chemoattractant protein-1 in human peritoneal mesothelial cells: involvement of protein kinase C. | 2001-04 |
|
| Head injury. | 2001-04 |
|
| Transcytosis of retinol-binding protein across renal proximal tubule cells after megalin (gp 330)-mediated endocytosis. | 2001-04 |
|
| Methemoglobin oxidation of N-acetylbenzidine to form a sulfinamide. | 2001-04 |
|
| Modulation of colonic barrier function by the composition of the commensal flora in the rat. | 2001-04 |
|
| A physiological analysis of hyponatremia: implications for patients on peritoneal dialysis. | 2001-03-31 |
|
| Ascorbate restores endothelium-dependent vasodilation impaired by acute hyperglycemia in humans. | 2001-03-27 |
|
| Celsior is superior to UW for graft preservation from non-heart-beating donors in a canine liver transplantation model. | 2001-03-27 |
|
| Pancreas preservation with Celsior solution in a pig autotransplantation model: comparative study with University of Wisconsin solution. | 2001-03-27 |
|
| Randomized clinical study comparing UW and Celsior solution in liver preservation for transplantation: preliminary results. | 2001-03-27 |
|
| Isolation and phenotypic characterization of Pseudomonas aeruginosa pseudorevertants containing suppressors of the catabolite repression control-defective crc-10 allele. | 2001-03-15 |
|
| Transport of poly amidoamine dendrimers across Madin-Darby canine kidney cells. | 2001-03-14 |
|
| Singlet oxygen generation from phosphatidylcholine hydroperoxide in the presence of copper. | 2001-03-02 |
|
| Melatonin counteracts potentiation by lysophosphatidylcholine of serotonin-induced vasoconstriction in human umbilical artery: relation to calcium influx. | 2001-03 |
|
| Identification of a mannitol transporter, AgMaT1, in celery phloem. | 2001-03 |
|
| Monosaccharide uptake in common carp (Cyprinus carpio) EPC cells is mediated by a facilitative glucose carrier. | 2001-03 |
|
| Modeling of supercritical extraction of mannitol from plane tree leaf. | 2001-03 |
|
| Mannitol-induced toxicity in a diabetic patient receiving losartan. | 2001-03 |
|
| Osmotherapy: a call to arms. | 2001-03 |
|
| Intraplatelet calcium levels in patients with acute renal failure before and after the administration of loop diuretics. | 2001-03 |
|
| Translocated EspF protein from enteropathogenic Escherichia coli disrupts host intestinal barrier function. | 2001-03 |
|
| The selective adenosine A1 receptor antagonist KW-3902 prevents radiocontrast media-induced nephropathy in rats with chronic nitric oxide deficiency. | 2001-02-23 |
|
| The combined hydrolysis and hydrogenation of inulin catalyzed by bifunctional Ru/C. | 2001-02-15 |
|
| Permeability of the proximal and distal rat colon crypt and surface epithelium to hydrophilic molecules. | 2001-02 |
|
| Preferential induction of a 9-lipoxygenase by salt in salt-tolerant cells of Citrus sinensis L. Osbeck. | 2001-02 |
|
| [Intraoperative complications of 697 consecutive operative hysteroscopies]. | 2001-02 |
|
| Intestinal permeability in adult patients with growth hormone deficiency. | 2001-02 |
|
| Improving water stress tolerance of the biocontrol yeast Candida sake grown in molasses-based media by physiological manipulation. | 2001-02 |
|
| The transmembrane protein occludin of epithelial tight junctions is a functional target for serine peptidases from faecal pellets of Dermatophagoides pteronyssinus. | 2001-02 |
|
| Pathophysiologic features and prevention of human and experimental acute tubular necrosis. | 2001-02 |
|
| Mannitol-induced acute manic state. | 2001-02 |
|
| The use of hypertonic saline in the treatment of traumatic brain injury. | 2001-02 |
|
| Combined injection of rAAV with mannitol enhances gene expression in the rat brain. | 2001-02 |
|
| Hyperosmotic stress induces a rapid and transient increase in inositol 1,4,5-trisphosphate independent of abscisic acid in Arabidopsis cell culture. | 2001-02 |
|
| Survey of the use of intracranial pressure monitoring in children in the United Kingdom. | 2001-01 |
|
| Membrane-bound sugar alcohol dehydrogenase in acetic acid bacteria catalyzes L-ribulose formation and NAD-dependent ribitol dehydrogenase is independent of the oxidative fermentation. | 2001-01 |
|
| Development of a lyophilized formulation for (R,R)-formoterol (L)-tartrate. | 2001-01 |
|
| Protective effects of fluvastatin against reactive oxygen species induced DNA damage and mutagenesis. | 2001-01 |
|
| Intestinal permeability tests in coeliac disease. | 2001 |
|
| Mannitol for acute stroke. | 2001 |
|
| Hypertonicity stimulates Cl(-) transport in the intestine of fresh water acclimated eel, Anguilla anguilla. | 2001 |
Sample Use Guides
In Vivo Use Guide
Curator's Comment: 3% sorbitol solution is used as irrigation solution during urinary tract surgery
https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=5f7be402-f25a-428e-b81f-6a4a00de894c&type=pdf&name=5f7be402-f25a-428e-b81f-6a4a00de894c
OSMITROL Injection (Mannitol Injection, USP) should be administered only by
intravenous infusion. The total dosage, concentration, and rate of administration should
be governed by the nature and severity of the condition being treated, fluid requirement,
and urinary output. The usual adult dosage ranges from 20 to 100 g in a 24 hour period,
but in most instances an adequate response will be achieved at a dosage of approximately
50 to 100 g in a 24 hour period. The rate of administration is usually adjusted to maintain
a urine flow of at least 30 to 50 mL/hour. This outline of administration and dosage is
only a general guide to therapy.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24706609
Curator's Comment: The effects of allopurinol (10(-6)-10(-5) M), deferoxamine (10(-4) M) and mannitol (10(-4)-5 x 10(-3) M) were tested on the transient contraction induced by nicotine. In conclusion, mannitol (5 x 10(-3) M) significantly reduced contractile response to nicotine on EFS only in high concentration. Whereas in small concentrations mannitol (10(-4) M) statistically did not cause any results. https://www.ncbi.nlm.nih.gov/pubmed/20085573
Four different iodinated X-ray contrast agents--three of them with two different iodine concentrations--and mannitol (negative control; concentration of 150 mg mannitol per ml blood) were pipetted into blood samples so that there was a concentration of 0, 7.5 or 15 mg of iodine per ml blood in the samples.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-VATC |
QV04CC01
Created by
admin on Mon Mar 31 17:52:44 GMT 2025 , Edited by admin on Mon Mar 31 17:52:44 GMT 2025
|
||
|
EPA PESTICIDE CODE |
8
Created by
admin on Mon Mar 31 17:52:44 GMT 2025 , Edited by admin on Mon Mar 31 17:52:44 GMT 2025
|
||
|
FDA ORPHAN DRUG |
422914
Created by
admin on Mon Mar 31 17:52:44 GMT 2025 , Edited by admin on Mon Mar 31 17:52:44 GMT 2025
|
||
|
DSLD |
1712 (Number of products:9)
Created by
admin on Mon Mar 31 17:52:44 GMT 2025 , Edited by admin on Mon Mar 31 17:52:44 GMT 2025
|
||
|
NCI_THESAURUS |
C218
Created by
admin on Mon Mar 31 17:52:44 GMT 2025 , Edited by admin on Mon Mar 31 17:52:44 GMT 2025
|
||
|
WHO-ATC |
V04CC01
Created by
admin on Mon Mar 31 17:52:44 GMT 2025 , Edited by admin on Mon Mar 31 17:52:44 GMT 2025
|
||
|
CFR |
21 CFR 184.1835
Created by
admin on Mon Mar 31 17:52:44 GMT 2025 , Edited by admin on Mon Mar 31 17:52:44 GMT 2025
|
||
|
WHO-VATC |
QB05CX02
Created by
admin on Mon Mar 31 17:52:44 GMT 2025 , Edited by admin on Mon Mar 31 17:52:44 GMT 2025
|
||
|
LOINC |
48152-3
Created by
admin on Mon Mar 31 17:52:44 GMT 2025 , Edited by admin on Mon Mar 31 17:52:44 GMT 2025
|
||
|
WHO-ATC |
A06AD18
Created by
admin on Mon Mar 31 17:52:44 GMT 2025 , Edited by admin on Mon Mar 31 17:52:44 GMT 2025
|
||
|
WHO-ATC |
A06AG07
Created by
admin on Mon Mar 31 17:52:44 GMT 2025 , Edited by admin on Mon Mar 31 17:52:44 GMT 2025
|
||
|
CODEX ALIMENTARIUS (GSFA) |
INS-420(I)
Created by
admin on Mon Mar 31 17:52:44 GMT 2025 , Edited by admin on Mon Mar 31 17:52:44 GMT 2025
|
||
|
EU-Orphan Drug |
EU/3/14/1260
Created by
admin on Mon Mar 31 17:52:44 GMT 2025 , Edited by admin on Mon Mar 31 17:52:44 GMT 2025
|
||
|
JECFA EVALUATION |
INS-420(I)
Created by
admin on Mon Mar 31 17:52:44 GMT 2025 , Edited by admin on Mon Mar 31 17:52:44 GMT 2025
|
||
|
WHO-VATC |
QA06AG07
Created by
admin on Mon Mar 31 17:52:44 GMT 2025 , Edited by admin on Mon Mar 31 17:52:44 GMT 2025
|
||
|
WHO-VATC |
QA06AD18
Created by
admin on Mon Mar 31 17:52:44 GMT 2025 , Edited by admin on Mon Mar 31 17:52:44 GMT 2025
|
||
|
WHO-ATC |
B05CX02
Created by
admin on Mon Mar 31 17:52:44 GMT 2025 , Edited by admin on Mon Mar 31 17:52:44 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
506T60A25R
Created by
admin on Mon Mar 31 17:52:44 GMT 2025 , Edited by admin on Mon Mar 31 17:52:44 GMT 2025
|
PRIMARY | |||
|
506T60A25R
Created by
admin on Mon Mar 31 17:52:44 GMT 2025 , Edited by admin on Mon Mar 31 17:52:44 GMT 2025
|
PRIMARY | |||
|
CHEMBL1682
Created by
admin on Mon Mar 31 17:52:44 GMT 2025 , Edited by admin on Mon Mar 31 17:52:44 GMT 2025
|
PRIMARY | |||
|
DTXSID5023588
Created by
admin on Mon Mar 31 17:52:44 GMT 2025 , Edited by admin on Mon Mar 31 17:52:44 GMT 2025
|
PRIMARY | |||
|
D013012
Created by
admin on Mon Mar 31 17:52:44 GMT 2025 , Edited by admin on Mon Mar 31 17:52:44 GMT 2025
|
PRIMARY | |||
|
17924
Created by
admin on Mon Mar 31 17:52:44 GMT 2025 , Edited by admin on Mon Mar 31 17:52:44 GMT 2025
|
PRIMARY | |||
|
SORBITOL
Created by
admin on Mon Mar 31 17:52:44 GMT 2025 , Edited by admin on Mon Mar 31 17:52:44 GMT 2025
|
PRIMARY | |||
|
1617000
Created by
admin on Mon Mar 31 17:52:44 GMT 2025 , Edited by admin on Mon Mar 31 17:52:44 GMT 2025
|
PRIMARY | |||
|
SUB12594MIG
Created by
admin on Mon Mar 31 17:52:44 GMT 2025 , Edited by admin on Mon Mar 31 17:52:44 GMT 2025
|
PRIMARY | |||
|
DB01638
Created by
admin on Mon Mar 31 17:52:44 GMT 2025 , Edited by admin on Mon Mar 31 17:52:44 GMT 2025
|
PRIMARY | |||
|
C29462
Created by
admin on Mon Mar 31 17:52:44 GMT 2025 , Edited by admin on Mon Mar 31 17:52:44 GMT 2025
|
PRIMARY | |||
|
100000092096
Created by
admin on Mon Mar 31 17:52:44 GMT 2025 , Edited by admin on Mon Mar 31 17:52:44 GMT 2025
|
PRIMARY | |||
|
m10121
Created by
admin on Mon Mar 31 17:52:44 GMT 2025 , Edited by admin on Mon Mar 31 17:52:44 GMT 2025
|
PRIMARY | Merck Index | ||
|
SUB20837
Created by
admin on Mon Mar 31 17:52:44 GMT 2025 , Edited by admin on Mon Mar 31 17:52:44 GMT 2025
|
PRIMARY | |||
|
25944
Created by
admin on Mon Mar 31 17:52:44 GMT 2025 , Edited by admin on Mon Mar 31 17:52:44 GMT 2025
|
PRIMARY | |||
|
2462
Created by
admin on Mon Mar 31 17:52:44 GMT 2025 , Edited by admin on Mon Mar 31 17:52:44 GMT 2025
|
PRIMARY | |||
|
5780
Created by
admin on Mon Mar 31 17:52:44 GMT 2025 , Edited by admin on Mon Mar 31 17:52:44 GMT 2025
|
PRIMARY | |||
|
9945
Created by
admin on Mon Mar 31 17:52:44 GMT 2025 , Edited by admin on Mon Mar 31 17:52:44 GMT 2025
|
PRIMARY | RxNorm | ||
|
200-061-5
Created by
admin on Mon Mar 31 17:52:44 GMT 2025 , Edited by admin on Mon Mar 31 17:52:44 GMT 2025
|
PRIMARY | |||
|
50-70-4
Created by
admin on Mon Mar 31 17:52:44 GMT 2025 , Edited by admin on Mon Mar 31 17:52:44 GMT 2025
|
PRIMARY | |||
|
801
Created by
admin on Mon Mar 31 17:52:44 GMT 2025 , Edited by admin on Mon Mar 31 17:52:44 GMT 2025
|
PRIMARY | |||
|
30911
Created by
admin on Mon Mar 31 17:52:44 GMT 2025 , Edited by admin on Mon Mar 31 17:52:44 GMT 2025
|
PRIMARY |
ACTIVE MOIETY